Use Salix Pharmaceuticals Ltd. story together with your assets to enhance returns of your portfolios as well as to check it against diversification policy that fits your risk preferences.
This story from stocks.us.reuters.com contributed to next trading day price decline. The story delta to the next closing price was 1.02% . The story delta to the current price is 38.74% .
IT Business Net - May 10, 2012
By GrabNetworks Salix Pharmaceuticals (SLXP) today had its estimates increased by Jefferies (JEF) after the company beat earnings estimates.
Junction Report - May 9, 2012
Salix Pharmaceuticals (NASDAQ: SLXP)'s stock had its ?neutral? rating restated by Zacks in a report issued on Wednesday. They currently have a $55.00 target price on the stock.
Auriga Reiterates Hold on Salix Pharmaceuticals (SLXP) - Movie News Guide (blog)
StreetInsider.com (subscription) - May 8, 2012
Jefferies analysts raised their price target on Salix Pharmaceuticals (NASDAQ: SLXP) from $54.00 to $63.00 while maintaining a BUY rating on the company.
Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investor or analyst to check on the quality of a company earnings.
USA 
Equity Search
Advanced Search
Market Screener
Adviser Directory
Suggest Portfolio
Backtest Watchlist
Analyze Correlations
View Transactions
Check Volatility
Import Equities
Summary
Fundamentals
Technicals
Performance
Valuation
Volatility
History
News
Management
Discussion
